The Next Wave Of US Humira Biosimilars
Generics Bulletin Explains The Coming Adalimumab Competitors
Following Amgen’s debut of the first US Humira rival earlier this year, as many as eight further FDA-approved adalimumab biosimilars are about to launch. Generics Bulletin breaks down all the different players and how they are positioning themselves in such a competitive market.
